Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 16/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882480 | 0.94 | PGR (0.53) | PGRARCYP11B1CYP11B2 | |
| SCHEMBL2882456 | 0.92 | PGR (0.54) | PGRARCYP11B1CYP11B2 | |
| SCHEMBL2881765 | 0.86 | PGR (0.56) | PGRARCYP11B1CYP11B2 | |
| SCHEMBL2882098 | 0.85 | PGR (0.56) | PGRARCYP11B1CYP11B2 | |
| SCHEMBL14068908 | 0.84 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL2883211 | 0.82 | CYP11B1 (0.54) | PGRARCYP11B1 | |
| SCHEMBL2882333 | 0.79 | PGR (0.58) | PGRARCYP11B1CYP11B2 | |
| SCHEMBL2881867 | 0.75 | PGR (0.51) | PGRAR | |
| SCHEMBL10192149 | 0.73 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL2882290 | 0.72 | MAPT (0.53) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750038-B2 | Sulfonylated heterocycles useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-07-06 | — | — | US | claimed |
| EP-2121657-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008109056-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-11 | — | — | US | claimed |
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-7750038-B2 | Sulfonylated heterocycles useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750038-B2 | Sulfonylated heterocycles useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750038-B2 | Sulfonylated heterocycles useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2121657-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109056-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | GNRHR, FSHR, PRLHR | PGR 5/4885AR 83/4885CYP11B1 987/4885 |
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | GNRHR, FSHR, PRLHR | PGR 5/4885AR 83/4885CYP11B1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.